Solid Biosciences opened lower at $7.59, compared with its previous close of $7.60. In the last trading session, the stock traded between $6.97 and $7.59. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Solid Biosciences is now worth
$ 21.62
Resulting in a loss of
$ 78.38 (78.38%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 11 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.60 (-7.83%)
Day High
$7.59
Day Low
$6.97
Day Open
$7.59
Prev Close
$7.60
Volume
10,95,692
1W Return
7.47%
1M Return
4.63%
3M Return
-20.98%
6M Return
-8.79%
1Y Return
54.64%
Fundamentals
Market Cap ($ Mn)
782
PE Ratio
-
PB Ratio
2.75
PEG Ratio
-
ROE
-80.12%
ROCE
-77.58%
EPS (TTM)
$-0.48
Investment Returns
1 Week
7.47%
1 Month
4.63%
3 Months
-20.98%
6 Months
-8.79%
9 Months
9.45%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
16Oct
UBS initiates coverage on Solid Biosciences with Buy rating
UBS initiated coverage on Solid Biosciences with a Buy rating. Analyst Joon Lee set a price target of $20 per share. The rating indicates a positive outlook for the biotech company.
28 days ago
2Oct
Solid Biosciences grants 8,150 RSUs to new employee
Solid Biosciences granted 8,150 restricted stock units to one new employee. The award falls under the 2024 Inducement Stock Incentive Plan. RSUs vest in four equal annual installments over four years. Grant complies with Nasdaq Listing Rule 5635(c)(4).
1mo ago
21Aug
Truist raises Solid Biosciences price target to $20 on Buy
Truist Securities maintains Buy rating on Solid Biosciences. Price target raised from $16 to $20. Analyst Danielle Brill leads the coverage. No specific financial results disclosed in note.
2mo ago
7Aug
Solid Biosciences Q2 Results: EPS beats estimates by 17.39%
Solid Biosciences delivered a second-quarter EPS of $(0.38), beating the consensus estimate of $(0.46) by 17.39%. The result reflects a 9.52% improvement in losses compared to the $(0.42) per share loss in the same period last year, signaling narrowing deficits.
